Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced…

Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced it has received an “Acceptance Letter” from the New York Stock Exchange (NYSE), confirming the NYSE’s approval of the Company’s plan to regain compliance with listing standards related to minimum market capitalization and stockholders’ equity. The NYSE has granted the Company an 18-month period, starting from the Notice of Noncompliance dated March 26, 2025 (the “Plan Period”), to meet the r…